Response to Trametinib of a Pulmonary Langerhans Cell Histiocytosis Harboring a MAP2K1 Deletion

Am J Respir Crit Care Med. 2018 Sep 1;198(5):675-678. doi: 10.1164/rccm.201802-0275LE.

Authors

Gwenaël Lorillon¹, Fanelie Jouenne^{1

2}, Barouyr Baroudjian¹, Constance de Margerie-Mellon^{1

2}, Laetitia Vercellino¹, Véronique Meignin^{1

3}, Celeste Lebbe^{1

2

4}, Robert Vassallo⁵, Samia Mourah^{1

2

4}, Abdellatif Tazi^{1

2

6}

Affiliations

¹ 1 Assistance Publique-Hôpitaux de Paris Paris, France.
² 2 Université Paris Diderot Paris, France.
³ 3 INSERM UMR_S1165 Paris, France.
⁴ 4 INSERM U976 Paris, France.
⁵ 5 Mayo Clinic Rochester, Minnesota and.
⁶ 6 U1153 CRESS Paris, France.

PMID: 29694792
DOI: 10.1164/rccm.201802-0275LE

No abstract available

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Antineoplastic Agents / therapeutic use*
Histiocytosis, Langerhans-Cell / diagnostic imaging
Histiocytosis, Langerhans-Cell / drug therapy*
Humans
Lung / diagnostic imaging
MAP Kinase Kinase 1 / deficiency*
Male
Pyridones / therapeutic use*
Pyrimidinones / therapeutic use*
Tomography, X-Ray Computed
Treatment Outcome

Substances

Antineoplastic Agents
Pyridones
Pyrimidinones
trametinib
MAP Kinase Kinase 1
MAP2K1 protein, human